Erratum: The ESMO Guidelines Working Group would like to publish the following corrections to manuscripts published in 2013 (Annals of Oncology (2013) 24(S6) (vi125–vi132), (S0923753419315595), (10.1093/annonc/mdt304));Testicular seminoma and non-seminoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 24, Issue SUPPL.6, 2013, Pages iii153-

  Oldenburg, J ^a   Fossa S D ^a   Nuver, J ^b   Heidenreich, A ^c   Schmoll, H J ^d   Bokemeyer, C ^e   Horwich, A ^f   Beyer, J ^g   Kataja, V ^h  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^c UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^d MARTIN LUTHER UNIVERSITÄT HALLE WITTENBERG   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^f ROYAL MARSDEN HOSPITAL   (United Kingdom)

^g VIVANTES KLINIKUM AM URBAN   (Germany)

^h KUOPIO UNIVERSITY HOSPITAL   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

BLEOMYCIN; CARBOPLATIN; CISPLATIN; ETOPOSIDE; FLUORODEOXYGLUCOSE; IFOSFAMIDE; PACLITAXEL; TUMOR MARKER; VINBLASTINE;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER RISK; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; JAPANESE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; ORCHIECTOMY; PERSONALIZED MEDICINE; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PRIMARY TUMOR; PRIORITY JOURNAL; RISK ASSESSMENT; SALVAGE THERAPY; SEMINOMA; TESTIS NONSEMINOMA CANCER; TREATMENT INDICATION; TREATMENT RESPONSE; TUMOR BIOPSY;

ANTINEOPLASTIC AGENTS; EUROPE; FOLLOW-UP STUDIES; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; ORCHIECTOMY; RISK ASSESSMENT; SALVAGE THERAPY; SEMINOMA; TESTICULAR NEOPLASMS; TREATMENT OUTCOME;

EID: 84885367736     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdu277     Document Type: Erratum

References (26)

1. Bray F, Richiardi L, Ekbom A et al. Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality. Int J Cancer 2006; 118: 3099-3111.
2. Elert A, Olbert P, Hegele A et al. Accuracy of frozen section examination of testicular tumors of uncertain origin. Eur Urol 2002; 41: 290-293.
3. Heidenreich A, Weissbach L, Holtl W et al. Organ sparing surgery for malignant germ cell tumor of the testis. J Urol 2001; 166: 2161-2165.
4. Beyer J, Albers P, Altena R et al. Maintaining success, reducing treatment burden, focusing on survivorship: highlights from the third European consensus conference on diagnosis and treatment of germ-cell cancer. Ann Oncol 2013; 24: 878-888.
5. International Germ Cell Cancer Collaborative Group. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. J Clin Oncol 1997; 15: 594-603.
6. Oliver RT, Mason MD, Mead GM et al. Radiotherapy versus single-dose carboplatin in adjuvant treatment of stage I seminoma: a randomised trial. Lancet 2005; 366: 293-300.
7. Oliver RT, Mead GM, Rustin GJ et al. Randomized trial of carboplatin versus radiotherapy for stage I seminoma: mature results on relapse and contralateral testis cancer rates in MRC TE19/EORTC 30982 study (ISRCTN27163214). J Clin Oncol 2011; 29: 957-962.
8. Oldenburg J, Alfsen GC, Waehre H, Fossa SD. Late recurrences of germ cell malignancies: a population-based experience over three decades. Br J Cancer 2006; 94: 820-827.
9. Tandstad T, Smaaland R, Solberg A et al. Management of seminomatous testicular cancer: a binational prospective population-based study from the Swedish Norwegian testicular cancer study group. J Clin Oncol 2011; 29: 719-725.
10. Horwich A, Dearnaley DP, Sohaib A et al. Neoadjuvant carboplatin before radiotherapy in stage IIA and IIB seminoma. Ann Oncol 2013; 24: 2104-2107.
11. de Wit R, Stoter G, Sleijfer DT et al. Four cycles of BEP versus four cycles of VIP in patients with intermediate-prognosis metastatic testicular non-seminoma: a randomized study of the EORTC Genitourinary Tract Cancer Cooperative Group. European Organization for Research and Treatment of Cancer. Br J Cancer 1998; 78: 828-832.
12. Bachner M, Loriot Y, Gross-Goupil M et al. 2-18fluoro-deoxy-D-glucose Positron emission tomograpshy (FDG-PET) for postchemotherapy seminoma residual lesions: a retrospective validation of the SEMPET trial. Ann Oncol 2012; 23: 59-64.
13. Tandstad T, Dahl O, Cohn-Cedermark G et al. Risk-adapted treatment in clinical stage I nonseminomatous germ cell testicular cancer: the SWENOTECA management program. J Clin Oncol 2009; 27: 2122-2128.
14. Feldman DR, Bosl GJ, Sheinfeld J, Motzer RJ. Medical treatment of advanced testicular cancer. JAMA 2008; 299: 672-684.
15. Fizazi K, Pagliaro LC, Flechon A et al. A phase III trial of personalized chemotherapy based on serum tumor marker decline in poor-prognosis germ-cell tumors: results of GETUG 13. J Clin Oncol 2013; 31 (Suppl. 18): LBA4500.
16. Ehrlich Y, Brames MJ, Beck SD et al. Long-term follow-up of cisplatin combination chemotherapy in patients with disseminated nonseminomatous germ cell tumors: is a postchemotherapy retroperitoneal lymph node dissection needed after complete remission? J Clin Oncol 2010; 28: 531-536.
17. Heidenreich A, Pfister D. Retroperitoneal lymphadenectomy and resection for testicular cancer: an update on best practice. Ther Adv Urol 2012; 4: 187-205.
18. Fizazi K, Oldenburg J, Dunant A et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 2008; 19: 259-264.
19. Lorch A, Beyer J, Bascoul-Mollevi C et al. Prognostic factors in patients with metastatic germ cell tumors who experienced treatment failure with cisplatinbased first-line chemotherapy. J Clin Oncol 2010; 28: 4906-4911.
20. Lorch A, Bascoul-Mollevi C, Kramar A et al. Conventional-dose versus high-dose chemotherapy as first salvage treatment in male patients with metastatic germ cell tumors: evidence from a large international database. J Clin Oncol 2011; 29: 2178-2184.
21. Pico JL, Rosti G, Kramar A et al. A randomised trial of high-dose chemotherapy in the salvage treatment of patients failing first-line platinum chemotherapy for advanced germ cell tumours. Ann Oncol 2005; 16: 1152-1159.
22. Lorch A, Neubauer A, Hackenthal M et al. High-dose chemotherapy (HDCT) as second-salvage treatment in patients with multiple relapsed or refractory germ-cell tumors. Ann Oncol 2010; 21: 820-825.
23. Oechsle K, Kollmannsberger C, Honecker F et al. Long-term survival after treatment with gemcitabine and oxaliplatin with and without paclitaxel plus secondary surgery in patients with cisplatin-refractory and/or multiply relapsed germ cell tumors. Eur Urol 2011; 60: 850-855.
24. Oldenburg J, Martin JM, Fossa SD. Late relapses of germ cell malignancies: incidence, management, and prognosis. J Clin Oncol 2006; 24: 5503-5511.
25. Brydoy M, Fossa SD, Klepp O et al. Paternity following treatment for testicular cancer. J Natl Cancer Inst 2005; 97: 1580-1588.
26. de Haas EC, Altena R, Boezen HM et al. Early development of the metabolic syndrome after chemotherapy for testicular cancer. Ann Oncol 2013; 24: 749-755.